Preclinical data suggest that temoporfin is the most promising orthosteric NS2B-NS3 protease inhibitor (NS2B-NS3 IC50 = 1.1 μM, cellular infection EC50 = 0.010–0.024 μM), exhibiting a strong reduction in peak viremia at low doses (2-log peak viremia reduction in ZIKV-infected Balb/c mice following 1.6 mg/kg IP). This evidence concerns the gene KRAS and infection.